The FDA has banned compounded versions of GLP-1 drugs like semaglutide or tirzepatide due to safety ... including B vitamins and BPC-157, a substance determined by the FDA as unsafe for compounding.

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

The analysis explored data from the trial to determine the association of tirzepatide treatment with changes in thigh muscle volume, muscle volume z-score and muscle fat infiltration in people ...

Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for starting doses.

The FDA has said it has agreed to reconsider its decision to prevent compounding pharmacies from producing and selling versions of Eli Lilly's diabetes and obesity drug tirzepatide. The US ...

Zepbound is a weekly injectable prescription weight loss medication with the active ingredient tirzepatide. It’s a GLP-1 agonist drug that slows stomach emptying, meaning you feel fuller for longer.

After it is injected, the drug may stay in your system for around 30 days. Mounjaro (tirzepatide) is a prescription medication that helps manage blood sugar levels in adults with type 2 diabetes.